

Guy Jerusalem

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6627946/publications.pdf>

Version: 2024-02-01

76
papers

7,026
citations

136950

32
h-index

66911

78
g-index

81
all docs

81
docs citations

81
times ranked

9692
citing authors

#	ARTICLE	IF	CITATIONS
1	Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. <i>Journal of the American Society of Echocardiography</i> , 2014, 27, 911-939.	2.8	1,051
2	Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. <i>Journal of Clinical Oncology</i> , 2018, 36, 2465-2472.	1.6	704
3	Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 671-686.	2.5	564
4	Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4594-4600.	1.6	553
5	Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 514-524.	27.0	482
6	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1688-1700.	10.7	451
7	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 371-382.	10.7	327
8	Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt337-djt337.	6.3	218
9	Triple-negative breast cancer: treatment challenges and solutions. <i>Breast Cancer: Targets and Therapy</i> , 2016, 8, 93.	1.8	201
10	Cardio-Oncology Services: rationale, organization, and implementation. <i>European Heart Journal</i> , 2019, 40, 1756-1763.	2.2	195
11	Codon-specific translation reprogramming promotes resistance to targeted therapy. <i>Nature</i> , 2018, 558, 605-609.	27.8	177
12	Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. <i>Lancet Oncology</i> , The, 2019, 20, 1360-1369.	10.7	131
13	Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer. <i>Oncotarget</i> , 2015, 6, 10253-10266.	1.8	130
14	18F-FDG PET in children with lymphomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 31-38.	6.4	109
15	Evaluation of Therapy for Lymphoma. <i>Seminars in Nuclear Medicine</i> , 2005, 35, 186-196.	4.6	98
16	Asporin Is a Fibroblast-Derived TGF- β 1 Inhibitor and a Tumor Suppressor Associated with Good Prognosis in Breast Cancer. <i>PLoS Medicine</i> , 2015, 12, e1001871.	8.4	97
17	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 127-138.	10.7	91
18	HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 237-250.	2.5	84

#	ARTICLE	IF	CITATIONS
19	Tissue Factor Induced by Epithelial-Mesenchymal Transition Triggers a Procoagulant State That Drives Metastasis of Circulating Tumor Cells. <i>Cancer Research</i> , 2016, 76, 4270-4282.	0.9	81
20	Natural Antisense Transcripts: Molecular Mechanisms and Implications in Breast Cancers. <i>International Journal of Molecular Sciences</i> , 2018, 19, 123.	4.1	69
21	Circulating microRNA-based screening tool for breast cancer. <i>Oncotarget</i> , 2016, 7, 5416-5428.	1.8	66
22	Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1089-1097.	6.3	59
23	Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients. <i>BMC Cancer</i> , 2018, 18, 102.	2.6	50
24	Ageism and its clinical impact in oncogeriatrics: state of knowledge and therapeutic leads. <i>Clinical Interventions in Aging</i> , 2015, 10, 117.	2.9	49
25	Group interventions to reduce emotional distress and fatigue in breast cancer patients: a 9-month follow-up pragmatic trial. <i>British Journal of Cancer</i> , 2017, 117, 1442-1449.	6.4	49
26	Metastatic colorectal cancer cells maintain the TGF β 2 program and use TGFBI to fuel angiogenesis. <i>Theranostics</i> , 2021, 11, 1626-1640.	10.0	45
27	Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. <i>Breast</i> , 2015, 24, 182-190.	2.2	44
28	Multidisciplinary rehabilitation program after breast cancer: benefits on physical function, anthropometry and quality of life. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2017, 53, 633-642.	2.2	44
29	Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer. <i>Current Medical Research and Opinion</i> , 2014, 30, 1007-1016.	1.9	42
30	Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 1838-1850.	7.0	41
31	Neoadjuvant Chemotherapy in Breast Cancer Patients Induces miR-34a and miR-122 Expression. <i>Journal of Cellular Physiology</i> , 2015, 230, 473-481.	4.1	39
32	Transcriptome-wide analysis of natural antisense transcripts shows their potential role in breast cancer. <i>Scientific Reports</i> , 2017, 7, 17452.	3.3	39
33	CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 283-298.	2.4	39
34	Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. <i>JCO Global Oncology</i> , 2021, 7, 162-172.	1.8	38
35	EGFR Activation and Signaling in Cancer Cells Are Enhanced by the Membrane-Bound Metalloprotease MT4-MMP. <i>Cancer Research</i> , 2014, 74, 6758-6770.	0.9	33
36	A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 95-117.	2.5	27

#	ARTICLE	IF	CITATIONS
37	Effects of an intervention combining self-care and self-hypnosis on fatigue and associated symptoms in post-treatment cancer patients: A randomized-controlled trial. <i>Psycho-Oncology</i> , 2020, 29, 1165-1173.	2.3	26
38	Positron emission tomography imaging for lymphoma. <i>Current Opinion in Oncology</i> , 2005, 17, 441-445.	2.4	23
39	nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, 181-190.e2.	2.4	23
40	Optimal treatment in locally advanced cervical cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 657-671.	2.4	23
41	A new era of improving progression-free survival with dual blockade in postmenopausal HR+, HER2 ⁺ advanced breast cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 94-104.	7.7	22
42	BRCA1 germline mutation and glioblastoma development: report of cases. <i>BMC Cancer</i> , 2015, 15, 181.	2.6	22
43	Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology. <i>ESC Heart Failure</i> , 2017, 4, 312-318.	3.1	22
44	Blood eosinophilic relative count is prognostic for breast cancer and associated with the presence of tumor at diagnosis and at time of relapse. <i>Oncolmmunology</i> , 2020, 9, 1761176.	4.6	22
45	Health related quality of life in older patients with solid tumors and prognostic factors for decline. <i>Journal of Geriatric Oncology</i> , 2019, 10, 895-903.	1.0	20
46	The link between self-perceptions of aging, cancer view and physical and mental health of older people with cancer: A cross-sectional study. <i>Journal of Geriatric Oncology</i> , 2017, 8, 64-68.	1.0	19
47	Association between self-perception of aging, view of cancer and health of older patients in oncology: a one-year longitudinal study. <i>BMC Cancer</i> , 2017, 17, 614.	2.6	18
48	Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment. <i>Oncotarget</i> , 2018, 9, 33719-33733.	1.8	18
49	Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers. <i>BMC Cancer</i> , 2015, 15, 755.	2.6	17
50	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 1458.	3.7	17
51	Multidisciplinary management of breast cancer. <i>Archives of Public Health</i> , 2016, 74, 50.	2.4	15
52	Exercise and Education Program After Breast Cancer: Benefits on Quality of Life and Symptoms at 3, 6, 12, and 24 Months™ Follow-up. <i>Clinical Breast Cancer</i> , 2018, 18, e1189-e1204.	2.4	15
53	A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 8.	5.0	15
54	Immunity and Breast Cancer: Focus on Eosinophils. <i>Biomedicines</i> , 2021, 9, 1087.	3.2	15

#	ARTICLE	IF	CITATIONS
55	Unplanned hospitalizations in older patients with cancer: Occurrence and predictive factors. <i>Journal of Geriatric Oncology</i> , 2021, 12, 368-374.	1.0	14
56	MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib. <i>British Journal of Cancer</i> , 2017, 116, 742-751.	6.4	13
57	Mesenchymal Stem Cells Shed Amphiregulin at the Surface of Lung Carcinoma Cells in a Juxtacrine Manner. <i>Neoplasia</i> , 2015, 17, 552-563.	5.3	12
58	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021, 13, 4421.	3.7	12
59	First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study. <i>Breast</i> , 2018, 38, 144-149.	2.2	10
60	Ribociclib plus fulvestrant in the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 93-106.	2.4	9
61	Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2016, 10, BCBCR.S12443.	1.1	8
62	Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2019, 19, 47-57.	2.4	8
63	Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. <i>European Journal of Cancer</i> , 2022, 164, 39-51.	2.8	8
64	Randomized controlled trial of an 8-week intervention combining self-care and hypnosis for post-treatment cancer patients: study protocol. <i>BMC Cancer</i> , 2018, 18, 1113.	2.6	7
65	Impact of self-perception of aging on mortality of older patients in oncology. <i>Cancer Medicine</i> , 2020, 9, 2283-2289.	2.8	7
66	Hypnosis, Meditation, and Self-Induced Cognitive Trance to Improve Post-treatment Oncological Patients' Quality of Life: Study Protocol. <i>Frontiers in Psychology</i> , 2022, 13, 807741.	2.1	7
67	Randomized, Controlled Trial of an Intervention Combining Self-Care and Self-Hypnosis on Fatigue, Sleep, and Emotional Distress in Posttreatment Cancer Patients: 1-Year Follow-Up. <i>International Journal of Clinical and Experimental Hypnosis</i> , 2022, 70, 136-155.	1.8	7
68	Patterns of resource utilization and cost for postmenopausal women with hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer in Europe. <i>BMC Cancer</i> , 2015, 15, 787.	2.6	6
69	Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial. <i>Clinical Cancer Research</i> , 2021, 27, 504-512.	7.0	5
70	Correlation between hematological parameters and outcome in patients with locally advanced cervical cancer treated by concomitant chemoradiotherapy. <i>Cancer Medicine</i> , 2020, 9, 8432-8443.	2.8	4
71	Neutropenia management in patients receiving myelosuppressive polychemotherapy for early breast cancer in Belgium: BRONS study results. <i>Acta Clinica Belgica</i> , 2020, 75, 128-135.	1.2	3
72	Intérêt de lâ€™hypnose en oncologie et dans la pratique de lâ€™hépato-gastro-entérologie. <i>HEGEL - HEpato-GastroEntérologie Libérale</i> , 2017, NÂ° 1, 101-102.	0.0	3

#	ARTICLE	IF	CITATIONS
73	Psycho-oncology interventions focusing on fatigue and sleep disturbances. <i>Current Opinion in Oncology</i> , 2022, 34, 270-278.	2.4	3
74	Exploratory Controlled Study of the Impact of a Hypnosis-Based Intervention on the Couple's Communication and Coping in the Context of Cancer. <i>International Journal of Clinical and Experimental Hypnosis</i> , 2021, 69, 261-276.	1.8	2
75	Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR ⁺ HER2 ⁻ Advanced Breast Cancer in the MONALEESA-3 Trial. <i>Clinical Breast Cancer</i> , 2022, 22, 326-335.	2.4	2
76	Cutaneous Breast Cancer Metastases Successfully Treated Using an Oxygen Flow Assisted Topical Administration of Methotrexate (OFAMTX). <i>Dermatology and Therapy</i> , 2020, 10, 855-861.	3.0	1